Lyell Immunopharma (LYEL) Retained Earnings: 2020-2025
Historic Retained Earnings for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -$1.5 billion.
- Lyell Immunopharma's Retained Earnings fell 28.24% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 28.24%. This contributed to the annual value of -$1.3 billion for FY2024, which is 34.23% down from last year.
- Per Lyell Immunopharma's latest filing, its Retained Earnings stood at -$1.5 billion for Q3 2025, which was down 2.70% from -$1.4 billion recorded in Q2 2025.
- Lyell Immunopharma's 5-year Retained Earnings high stood at -$451.8 million for Q2 2021, and its period low was -$1.5 billion during Q3 2025.
- In the last 3 years, Lyell Immunopharma's Retained Earnings had a median value of -$1.1 billion in 2024 and averaged -$1.2 billion.
- Data for Lyell Immunopharma's Retained Earnings shows a maximum YoY tumbled of 74.88% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Lyell Immunopharma's Retained Earnings stood at -$584.4 million in 2021, then crashed by 31.34% to -$767.5 million in 2022, then tumbled by 30.57% to -$1.0 billion in 2023, then slumped by 34.23% to -$1.3 billion in 2024, then decreased by 28.24% to -$1.5 billion in 2025.
- Its Retained Earnings stands at -$1.5 billion for Q3 2025, versus -$1.4 billion for Q2 2025 and -$1.4 billion for Q1 2025.